Jump to main content
Jump to site search

Issue 4, 2016
Previous Article Next Article

Profiling the estimated plasma concentrations of 215 marketed oral drugs

Author affiliations

Abstract

The human pharmacokinetic parameters of 215 marketed oral drugs have been collated and their estimated plasma concentrations (following repeat dosing) profiled against time using a one-compartment model. The estimated ratio of maximum to minimum plasma concentration for most drugs was observed to be less than 30, and the observed human toxicity of a subset of 104 drugs showed that most displayed adverse effects at a free plasma concentration of greater than 100 nM. These two observations can be combined to form a new definition for oral drug-likeness: a drug's ratio of maximum to minimum plasma concentration should aim to be less than 30 and its maximum free plasma concentration should preferably be at most 100 nM for a therapeutic dose that is likely to be absorbed. Assessment of new compounds against this proposal can be facilitated by use of in silico ADME models and an understanding of the relevant tolerances associated to prediction errors, allowing decisions to be made on the likelihood of a compound having an optimum pharmacokinetic profile.

Graphical abstract: Profiling the estimated plasma concentrations of 215 marketed oral drugs

Back to tab navigation

Supplementary files

Publication details

The article was received on 16 Dec 2015, accepted on 21 Jan 2016 and first published on 22 Jan 2016


Article type: Research Article
DOI: 10.1039/C5MD00583C
Citation: Med. Chem. Commun., 2016,7, 706-719

  •   Request permissions

    Profiling the estimated plasma concentrations of 215 marketed oral drugs

    M. C. Wenlock, Med. Chem. Commun., 2016, 7, 706
    DOI: 10.1039/C5MD00583C

Search articles by author

Spotlight

Advertisements